264 related articles for article (PubMed ID: 37370140)
21. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
22. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Wilkerson PM; Dedes KJ; Samartzis EP; Dedes I; Lambros MB; Natrajan R; Gauthier A; Piscuoglio S; Töpfer C; Vukovic V; Daley F; Weigelt B; Reis-Filho JS
Oncotarget; 2017 Jan; 8(4):6057-6066. PubMed ID: 28002809
[TBL] [Abstract][Full Text] [Related]
24. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Wilson AJ; Sarfo-Kantanka K; Barrack T; Steck A; Saskowski J; Crispens MA; Khabele D
Gynecol Oncol; 2016 Oct; 143(1):143-151. PubMed ID: 27444036
[TBL] [Abstract][Full Text] [Related]
25. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G
Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463
[TBL] [Abstract][Full Text] [Related]
26. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
27. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Ip LR; Poulogiannis G; Viciano FC; Sasaki J; Kofuji S; Spanswick VJ; Hochhauser D; Hartley JA; Sasaki T; Gewinner CA
Oncotarget; 2015 Apr; 6(12):10548-62. PubMed ID: 25868852
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
Zong D; Adam S; Wang Y; Sasanuma H; Callén E; Murga M; Day A; Kruhlak MJ; Wong N; Munro M; Ray Chaudhuri A; Karim B; Xia B; Takeda S; Johnson N; Durocher D; Nussenzweig A
Mol Cell; 2019 Mar; 73(6):1267-1281.e7. PubMed ID: 30704900
[TBL] [Abstract][Full Text] [Related]
29. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
30. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
Yanaihara N; Yoshino Y; Noguchi D; Tabata J; Takenaka M; Iida Y; Saito M; Yanagida S; Iwamoto M; Kiyokawa T; Chiba N; Okamoto A
Gynecol Oncol; 2023 Jan; 168():83-91. PubMed ID: 36403366
[TBL] [Abstract][Full Text] [Related]
32. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
33. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
34. TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
Moudry P; Watanabe K; Wolanin KM; Bartkova J; Wassing IE; Watanabe S; Strauss R; Troelsgaard Pedersen R; Oestergaard VH; Lisby M; Andújar-Sánchez M; Maya-Mendoza A; Esashi F; Lukas J; Bartek J
J Cell Biol; 2016 Feb; 212(3):281-8. PubMed ID: 26811421
[TBL] [Abstract][Full Text] [Related]
35. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
36. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
[TBL] [Abstract][Full Text] [Related]
37. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
[TBL] [Abstract][Full Text] [Related]
38. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
39. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Kaplan AR; Gueble SE; Liu Y; Oeck S; Kim H; Yun Z; Glazer PM
Sci Transl Med; 2019 May; 11(492):. PubMed ID: 31092693
[TBL] [Abstract][Full Text] [Related]
40. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
Pratz KW; Koh BD; Patel AG; Flatten KS; Poh W; Herman JG; Dilley R; Harrell MI; Smith BD; Karp JE; Swisher EM; McDevitt MA; Kaufmann SH
Clin Cancer Res; 2016 Aug; 22(15):3894-902. PubMed ID: 26979391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]